In May 2016 DiaSorin purchased the Focus Diagnostics products business including molecular diagnostics, ELISA and IFA.
DiaSorin has acquired all of the assets to develop, manufacture and distribute these products and will continue to manufacture the Focus Diagnostics range of products from the company’s facility in Cypress, California, USA, under the new name of DiaSorin Molecular LLC.
This acquired business is part of DiaSorin’s strategy to enhance and develop its product portfolio in specialist molecular infectious disease testing.
In Australia and New Zealand Focus Diagnostics’ products have been distributed by Southern Cross Diagnostics (SCD) over the past several years. SCD has developed a strong and supportive presence with this portfolio of products in the Australian and New Zealand IVD market.
DiaSorin Australia and SCD are currently undertaking an amicable transition of the products to DiaSorin Australia. This will include the appointment of Dr. Jeff Chan to the position of Molecular Diagnostics Product Manager for DiaSorin Australia and an ongoing consultancy with Mr. Nick Thliveris, Director of SCD, to support the transition and development of the business.
Currently the transition is expected to be complete on 1st December 2016 and from this day all sales, technical support, and service support will be provided by DiaSorin Australia.
SCD will continue the distribution of its existing life science and diagnostics brands, including Biocell and Bordier.
We would like to take this opportunity to thank our customers for their loyalty and support.